Emergent BioSolutions Inc. (0IGA.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Emergent BioSolutions Inc.
Address
400 Professional Drive
Gaithersburg, MD 20879
United States of America (the)
Phone
240 631 3200
Sector
Healthcare
Industry
Biotechnology
Employees
900
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Joseph C. Papa Jr. | Chief Executive Officer, President & Director | 2.49M | 1956 |
| Paul Williams | Senior Vice President of Products Business | 765,052 | 1967 |
| Simon C. Lowry | Chief Medical Officer & Head of Research and Development | 845,170 | 1973 |
| Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | 1.04M | 1971 |
| Richard S. Lindahl | Executive VP & CFO | 1.1M | 1964 |
| William Hartzel | Senior Vice President of Manufacturing & Bioservices | 1.39M | 1978 |
| Frank Vargo | VP & Treasurer | 0 | N/A |
| Jessica Perl | Senior Vice President, Corporate Secretary & General Counsel | 0 | 1981 |
| Michelle Pepin | Senior Vice President & Chief Human Resource Officer | 0 | N/A |
| Stephanie Duatschek | Chief Global Strategy & Franchise Development Officer | 0 | N/A |
Description
Emergent BioSolutions Inc. is a life sciences enterprise dedicated to developing and delivering solutions for preparing for and responding to diverse public health threats (PHTs) in the United States. Its mission involves countering unforeseen, intentional, and naturally arising health crises affecting populations. The company's product portfolio addresses a wide spectrum of PHTs, encompassing chemical, biological, radiological, nuclear, and explosive agents (CBRNE), emergent infectious diseases, travel-related health concerns, and immediate emergency medical needs. Among its key commercialized offerings are: Vaccines: BioThrax (for anthrax), ACAM2000 (for smallpox), Vivotif (an oral immunization against typhoid fever), and Vaxchora (a single-dose oral vaccine for cholera). Treatments & Antidotes: Botulism Antitoxin Heptavalent (combats botulism), vaccinia immune globulin intravenous (manages adverse reactions to smallpox vaccination), raxibacumab and Anthrasil (both for treating and preventing inhalational anthrax), and NARCAN (a nasal spray for immediate intervention in known or suspected opioid overdoses). Other Emergency Preparedness: Reactive skin decontamination lotion kits, and Trobigard, an investigational auto-injector product combining both drug and device components. Furthermore, Emergent BioSolutions boasts an active development pipeline, featuring candidates such as AP003 (a multidose Naloxone nasal spray), AP007 (a sustained-release Nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus-like particle vaccine), COVID-HIG (a treatment for SARS-CoV2), EGRD-001 (a diazepam auto-injector), SIAN (an antidote for acute cyanide poisoning), and UniFlu (a universal influenza vaccine). Beyond its proprietary products, the company also provides comprehensive contract development and manufacturing (CDMO) services. These services include drug substance and product manufacturing, packaging solutions, alongside specialized expertise in technology transfer, process optimization, and analytical development. Established in 1998, Emergent BioSolutions maintains its corporate headquarters in Gaithersburg, Maryland.
